Area of research
Molecular Biology · Oncology
Research interest
Research interests include Cancer-related gene regulation, Fibroblast Growth Factor Research, HER2/EGFR in Cancer Research, and Lung Cancer Treatments and Mutations.
Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model
Discovery of amyloid binders as chemical chaperone to block pathological α-synuclein aggregation in synucleinopathies
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2.
CDK12 condensation in nuclear speckles confers sensitivity to cyclin K molecular glue degraders
A palmitoylation-depalmitoylation relay spatiotemporally controls GSDMD activation in pyroptosis.
Inhibitor Development for α-Synuclein Fibril’s Disordered Region to Alleviate Parkinson’s Disease Pathology
Polyimide (PI) Composite Spunlace Nonwovens for Hygiene Material with Excellent Comfort and Antimicrobial Properties
Structure-based development of potent and selective type-II kinase inhibitors of RIPK1
YY1 downregulation underlies therapeutic response to molecular targeted agents.
YY1 downregulation underlies therapeutic response to molecular targeted agents
Structural mechanism for specific binding of chemical compounds to amyloid fibrils
Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.
Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads.
Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Supplementary Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Data from Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer
Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer.
Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer
Nanodrugs Incorporating LDHA siRNA Inhibit M2-like Polarization of TAMs and Amplify Autophagy to Assist Oxaliplatin Chemotherapy against Colorectal Cancer
Predicting the Onset of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure
Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer.
SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer.
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Discovery of a cooperative mode of inhibiting RIPK1 kinase.